Nuwellis Revenue Surges 14% Amidst Improved Margins

Nuwellis Inc. reported significant financial improvements for the second quarter of 2026, with revenue increasing by 14% to $1.97 million. U.S. revenue saw a notable 17% rise. The company also expanded its installed base by selling 24 consoles in the first half of 2026, compared to only 5 in the same period last year. A key highlight was the substantial increase in gross margin, which rose to 76% from 56% in the prior-year quarter. This improvement is attributed to higher pricing strategies and benefits from contract manufacturing.

The company is making progress on its pediatric label expansion, aiming to include patients weighing 5 kg and above, with a planned U.S. Food and Drug Administration submission in the fourth quarter of 2026. Further strengthening its financial position, Nuwellis raised approximately $12.7 million in gross proceeds through recent financing activities. Additionally, the company received a notice of allowance for its dual-lumen midline catheter technology, potentially facilitating less invasive peripheral access for extracorporeal therapies.

Despite revenue growth, Nuwellis recorded a net loss of approximately $4.8 million for Q2 2026. Operating expenses also increased to $4.7 million. As of June 30, 2026, the company's cash position stood at $3.9 million, underscoring its continued reliance on external financing. International service and rental revenue were lower, impacting overall growth. Nuwellis faces ongoing risks related to regulatory approvals and product development, with its Clarity Prime product not anticipated to launch until 2027.